Heart Rhythm Medicine, Health, Cycling, Fitness.
You can mark August 2011 as an amazing month for news in the treatment of atrial fibrillation (AF). In this post, I will attempt to share what I have learned about the two new blood-thinning drugs, apixaban and rivaroxaban–both Factor Xa inhibitors. (Disclaimer: this is not a book chapter, rather a blog post from a [...]
{ Comments on this entry are closed }
The unrelenting epidemic of inactivity and excessive eating wreaks havoc on more than just the heart and blood vessels. Lugging around extra weight also breaks down the joints and back. For evidence, look no further than the waiting room of any orthopedist; the people waiting for joint replacements look the same as those waiting to [...]
{ Comments on this entry are closed }
The dabigatran party isn’t even cleaned-up yet, when another warfarin competitor has hit the press wires. As reported on Cardiobrief from a Bayer press release, Rivaroxaban (Xarelto) was as effective as warfarin in stroke prevention in patients’ with AF. A composite of major and minor bleeding events were also similar to warfarin. Rivaroxaban is a [...]
{ Comments on this entry are closed }
I have heard this for years, “Doc, that stuff is rat poison!” But only lately have I heard this, “Doctor M, that company who can’t talk about their drug brought lunch again today.” Well, it is finally here (well almost), the first warfarin substitute, dabigatran. Sine antiquity, or at least it seems that long, the blood [...]
{ Comments on this entry are closed }
This morning I am told, “Dr Mandrola, there are two ladies from this company, Boehinger Ingelheim, who need to to give you a secret, sealed envelope.” I wonder whether the department of Health and Human Services knows about this exciting new potential warfarin substitute. Surely they do, as replacing the ubiquitous blood thinner warfarin with [...]
{ Comments on this entry are closed }
Is there a flawless medical therapy: a “wonder-drug” devoid of adverse effects, or a procedure without complications? Of course not. It’s why we have clinical trials. An intervention for a disease is determined beneficial or not by a clinical trial–the new treatment versus no treatment, or the current treatment. It really is that simple. [...]
{ Comments on this entry are closed }
